Clinical Trial Update: Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase II trial of an unspecified anti-angiogenic agent in combination with chemotherapy for second-line metastatic colorectal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Colorectal Cancer (CRC) | Phase 2 | Status: COMPLETED